首页> 外文会议>Conference on Biomarkers in AKI (Acute Kidney Injury) >Differential Diagnosis of AKI in Clinical Practice by Functional and Damage Biomarkers: Workgroup Statements from the Tenth Acute Dialysis Quality Initiative Consensus Conference
【24h】

Differential Diagnosis of AKI in Clinical Practice by Functional and Damage Biomarkers: Workgroup Statements from the Tenth Acute Dialysis Quality Initiative Consensus Conference

机译:功能和损伤生物标志物临床实践中AKI的鉴别诊断:第十次急性透析质量倡议协商会议的工作组陈述

获取原文

摘要

Acute kidney injury (AKI) is a common but complex clinical syndrome with multiple etiologies. These etiologies target different sites and pathways within the kidney. Novel biomarkers of kidney damage' (which can be tubular or glomerular) can be used to diagnose AKI, even in the absence of an increase in serum creatinine or oliguria. These biomarkers of kidney damage can be combined with biomarkers of kidney function to facilitate classification of AKI. A comprehensive review of the literature was performed using the published methodology of the Acute Dialysis Quality Initiative (ADQI) working group and used to establish consensus statements regarding the use of biomarkers in the differential diagnosis of AKI. We recommend that the pathophysiological terms 'functional change' and 'kidney damage' be used in preference to the anatomical classification using the terms pre-renal, renal and post-renal AKI. We further recommend the use of both renal and non-renal biomarkers in establishing the specific cause of AKI as soon as possible after diagnosis. The presence of underlying CKD or of sepsis poses additional challenges in differential diagnosis, since these conditions alter both baseline biomarker excretion and biomarker performance. We recommend that biomarkers be validated within the clinical context in which they are to be used. Within that context, combinations of biomarkers may, in the future, allow differentiation of the site, mechanism and phase of injury.
机译:急性肾损伤(AKI)是一种常见但复杂的临床综合征,具有多种病因。这些病因靶向肾脏内的不同部位和途径。肾脏损伤的新型生物标志物(可以是管状或肾小球)可用于诊断AKI,即使在没有血清肌酐或少尿的增加。这些肾脏损伤的生物标志物可以与肾功能的生物标志物相结合,以促进AKI的分类。使用急性透析质量倡议(ADQI)工作组(ADQI)工作组的公布方法进行了全面审查文献,并用于建立关于使用生物标志物在AKI的鉴别诊断中使用的共识陈述。我们建议使用术语前肾,肾和肾脏均衡术语的解剖学分类来使用病理生理学术语“功能变化”和“肾脏损伤”。我们进一步建议使用肾和非肾生物标志物在诊断后尽快建立AKI的具体原因。由于这些条件改变了基线生物标志物排泄和生物标志物性能,因此存在潜在的CKD或败血症在鉴别诊断中存在额外的挑战。我们建议在使用它们的临床背景下验证生物标志物。在这种情况下,生物标志物的组合可以在未来允许分化位点,机制和损伤的阶段。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号